Allergan Dose Finding Trials for AGN-199201 Oxymetazoline

In April 2011 we learnt that Vicept Therapeutics was undertaking some Phase 2 trials for their V-101 product. Now we see that Allergan, the new owners of V-101 are about to undertake some Dose Finding Phase 2 trials for the re-named AGN-199201.

Even though the 2011 announcement suggested that that trial was “designed to optimize the concentration of V-101 Cream in preparation for Phase III clinical testing in patients with erythematous rosacea and to further characterize the duration of the clinical effect”, more Phase 2 trials are to be taken.

Previous trials have examined 4 different concentrations and again 2 concentrations; this newly announced trial will examine 3 different concentrations against placebo. From this it would appear that the researchers are continuing to search for the best concentration to balance side effects with efficacy.

The trial record doesn’t detail the concentrations that will be examined.

The trial details suggest that 360 people will be recruited in Austin, Texas. This trial is scheduled to finish in November 2013.

What is Oxymetazoline?

Even though this trial doesn’t mention Oxymetazoline we know that that AGN-199201 is the code name for the oxymetazoline based product that Allergan purchased from Vicept Therapeutics.

Oxymetazoline is the active ingredient in decongestant products like Afrin, Sudafed OM and Vicks Sinex as well as in eye drops like Visine LR.

A well known side effect of Visine is rebound redness, where continued use leads to the redness that you were originally treating. Extended usage of Afrin can also lead to rebound nasal congestion.

Clinical Trial NCT01735201

NCT01735201: AGN-199201 for the Treatment of Erythema With Rosacea

Sponsor: Allergan

ClinicalTrials.gov Identifier: NCT01735201

First received: November 26, 2012

Estimated Enrollment: 360

Study Start Date: December 2012

Locations: Austin, Texas, United States

Estimated Study Completion Date: November 2013

Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)

This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

Primary Outcome Measures:

  • Change from Baseline In Erythema as Assessed by the Clinician’s Erythema Assessment (CEA) and Subject Self-Assessment (SSA) 5-Point Scales [ Time Frame: Baseline, Day 28 ]

Secondary Outcome Measures:

  • Change from Baseline In Erythema as Assessed by the CEA and SSA 5-Point Scales [ Time Frame: Baseline, Day 28 Hour 0.5 ]
  • Change from Baseline In Erythema as Assessed by the CEA and SSA 5-Point Scales [ Time Frame: Baseline, Day 28 Hour 1 ]

Inclusion Criteria:

  • Redness of the skin caused by rosacea

Exclusion Criteria:

  • ≥3 inflammatory lesions
  • Laser light-source or other energy based therapy in the last 6 months
  • Any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Subscribe

If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

2 Reader Comments

  1. Rebecca Jahren RN says:

    Good Day and Hello David Pascoe

    Thank You !!!! for ALL this Knowledge!!!!!!

    And by the way I appreciated your ‘article’/Comments on ” Dr Nase”

    Sorry to say = that Good Liars are hard to ID!!!
    AND when we are talking about those with NOT just one personality disorder …
    more than one or two or
    Borderline personality disorder
    Antisocial personality disorder
    Narcissistic personality disorder
    or even “cluster personality disorder” = multiple
    small percentage although ? which is not that uncommon.
    Especially if one is talking Dual Diagnosis’ with above AND Addictions Issues!!!
    Which in Hind Sight ……if it looks like a Duck …
    Then that takes us back to…Sorry to say = that Good Liars are hard to ID!!!
    Those of us that are “Good Eggs” it is so far from ‘us’.
    And by the way those with the ABOVE ARE NOT mentally ill …personality is
    the choice to do as they do…usually for bizarre HEh Heh I’m in control and LOVE to miss everyone/anything/to feel big=thats most of the reward…(also usually a percentage of sexual in there too) UGH..just all to Ugly..Ecky and Yuck.

    My point is Thank You for the difficulties = the site is here and excellent …I love your site!!!!
    I’ve been learning alot more/will continue to read further for quite awile!!!
    Knowledge is Empowerment!!

    Sincerely,
    Rebecca Jahren RN
    rnjahren@gmail.com

Leave a Comment

Top